These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26858440)

  • 1. Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease.
    Liu W; Struik D; Nies VJ; Jurdzinski A; Harkema L; de Bruin A; Verkade HJ; Downes M; Evans RM; van Zutphen T; Jonker JW
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2288-93. PubMed ID: 26858440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
    Lin Q; Huang Z; Cai G; Fan X; Yan X; Liu Z; Zhao Z; Li J; Li J; Shi H; Kong M; Zheng MH; Conklin DJ; Epstein PN; Wintergerst KA; Mohammadi M; Cai L; Li X; Li Y; Tan Y
    Hepatology; 2021 Jun; 73(6):2206-2222. PubMed ID: 32965675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation.
    Wang J; Zhang F; Yang W; Gao D; Yang L; Yu C; Chen C; Li X; Zhang JS
    FASEB J; 2023 Apr; 37(4):e22881. PubMed ID: 36934380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
    Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
    Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
    Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
    Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Trifolium pratense extract on methionine-choline-deficient diet-induced steatohepatitis in C57BL/6 mice.
    Chen T; Zhong FJ; Hong YM; Su WJ; Zhuang LL; Qiu LX
    Chin J Nat Med; 2014 Mar; 12(3):194-8. PubMed ID: 24702805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
    Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.
    Gao Q; Jia Y; Yang G; Zhang X; Boddu PC; Petersen B; Narsingam S; Zhu YJ; Thimmapaya B; Kanwar YS; Reddy JK
    Am J Pathol; 2015 May; 185(5):1396-408. PubMed ID: 25773177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoxyeicosatrienoic intervention improves NAFLD in leptin receptor deficient mice by an increase in PGC1α-HO-1-PGC1α-mitochondrial signaling.
    Raffaele M; Bellner L; Singh SP; Favero G; Rezzani R; Rodella LF; Falck JR; Abraham NG; Vanella L
    Exp Cell Res; 2019 Jul; 380(2):180-187. PubMed ID: 31039348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
    García-Ruiz I; Rodríguez-Juan C; Díaz-Sanjuán T; Martínez MA; Muñoz-Yagüe T; Solís-Herruzo JA
    Hepatology; 2007 Aug; 46(2):414-23. PubMed ID: 17654601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.
    Fang X; Du Z; Duan C; Zhan S; Wang T; Zhu M; Shi J; Meng J; Zhang X; Yang M; Zuo Y
    Life Sci; 2021 Apr; 270():118966. PubMed ID: 33482185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.
    Zhang QY; Zhao LP; Tian XX; Yan CH; Li Y; Liu YX; Wang PX; Zhang XJ; Han YL
    Hepatology; 2017 Sep; 66(3):834-854. PubMed ID: 28508477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.
    Stacchiotti A; Favero G; Lavazza A; Golic I; Aleksic M; Korac A; Rodella LF; Rezzani R
    PLoS One; 2016; 11(1):e0148115. PubMed ID: 26824477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
    Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
    Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.